{
  "nctId": "NCT04716426",
  "briefTitle": "APT™ T3X on the COVID-19 Contamination Rate",
  "officialTitle": "Use of APT™ T3X to Decrease the COVID-19 Contamination Rate in Humans",
  "protocolDocument": {
    "nctId": "NCT04716426",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-12-28",
    "uploadDate": "2021-04-06T13:03",
    "size": 205667,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04716426/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 100,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-01-28",
    "completionDate": "2021-03-25",
    "primaryCompletionDate": "2021-03-25",
    "firstSubmitDate": "2021-01-18",
    "firstPostDate": "2021-01-20"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* good general health (without serious health problems);\n* tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain real-time polymerase chain reaction (RT-PCR), for COVID-19.\n\nExclusion Criteria:\n\n* previous immunization against COVID-19;\n* allergy to tetracycline hydrochloride;\n* diagnosis of Lyme disease;\n* immunocompromised;\n* share housing with someone diagnosed with COVID-19 at the time of the baseline evaluation;\n* serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and metabolic diseases, etc.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "COVID-19 Contamination Rate.",
        "description": "Rate of how many people were infected with COVID-19 over the course of the study in each group.",
        "timeFrame": "22 days after randomization."
      }
    ],
    "secondary": [
      {
        "measure": "Number of Participants With Adverse Events",
        "description": "Number of participants who presented adverse events.",
        "timeFrame": "22 days after randomization."
      },
      {
        "measure": "Average Number of Adverse Events",
        "description": "Average number of adverse events over the course of the study.",
        "timeFrame": "22 days after randomization."
      },
      {
        "measure": "Days Over Which an Adverse Event Was Reported",
        "description": "Average days over which an adverse event was reported.",
        "timeFrame": "22 days after randomization."
      },
      {
        "measure": "Other Virus or Bacteria Contamination Rate.",
        "description": "Rate of how many people were infected with influenza or pneumonia over the course of the study in each group.",
        "timeFrame": "22 days after randomization."
      }
    ],
    "other": []
  },
  "realComplexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 2,
      "exclusionCount": 6,
      "totalCount": 8
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 71,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-21T22:32:24.259Z",
  "dataSource": "ClinicalTrials.gov API v2"
}